The risk of febrile neutropenia in breast cancer patients following adjuvant chemotherapy is predicted by the time course of interleukin-6 and C-reactive protein by modelling.
Ida NetterbergMats O KarlsonElisabet I NielsenAngelica L QuartinoHenrik LindmanLena E FribergPublished in: British journal of clinical pharmacology (2018)
The developed models add quantitative knowledge about IL-6 and CRP and their relationship to the development of FN. The study suggests that IL-6 may have potential as a clinical predictor of FN if monitored during myelosuppressive chemotherapy.